vs
NATIONAL PRESTO INDUSTRIES INC（NPK）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是NATIONAL PRESTO INDUSTRIES INC的1.3倍（$207.3M vs $164.0M），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 21.7%），NATIONAL PRESTO INDUSTRIES INC自由现金流更多（$12.4M vs $-100.8M），过去两年NATIONAL PRESTO INDUSTRIES INC的营收复合增速更高（46.3% vs 38.0%）
National Presto Industries创始于1905年，总部位于美国威斯康星州欧克莱尔，历经多次更名后于1953年确定现用名。该公司最初生产商用及后续家用压力锅，自1939年起推出小型家用烹饪电器，1969年在纽约证券交易所上市。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
NPK vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $164.0M | $207.3M |
| 净利润 | — | $-128.6M |
| 毛利率 | 16.9% | — |
| 营业利润率 | 11.4% | -54.7% |
| 净利率 | — | -62.0% |
| 营收同比 | 21.7% | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | — | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $164.0M | $207.3M | ||
| Q3 25 | $115.5M | $159.9M | ||
| Q2 25 | $120.4M | $166.5M | ||
| Q1 25 | $103.6M | $139.3M | ||
| Q4 24 | $134.7M | $164.6M | ||
| Q3 24 | $91.8M | $139.5M | ||
| Q2 24 | $85.1M | $147.0M | ||
| Q1 24 | $76.7M | $108.8M |
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $5.3M | $-180.4M | ||
| Q2 25 | $5.2M | $-115.0M | ||
| Q1 25 | $7.6M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $8.1M | $-133.5M | ||
| Q2 24 | $6.1M | $-131.6M | ||
| Q1 24 | $6.6M | $-170.7M |
| Q4 25 | 16.9% | — | ||
| Q3 25 | 13.9% | — | ||
| Q2 25 | 15.4% | — | ||
| Q1 25 | 17.5% | — | ||
| Q4 24 | 24.3% | — | ||
| Q3 24 | 18.8% | — | ||
| Q2 24 | 17.3% | — | ||
| Q1 24 | 18.1% | — |
| Q4 25 | 11.4% | -54.7% | ||
| Q3 25 | 5.6% | -106.9% | ||
| Q2 25 | 5.1% | -64.8% | ||
| Q1 25 | 8.8% | -102.6% | ||
| Q4 24 | 17.3% | -74.3% | ||
| Q3 24 | 10.0% | -94.6% | ||
| Q2 24 | 7.5% | -79.1% | ||
| Q1 24 | 8.2% | -151.9% |
| Q4 25 | — | -62.0% | ||
| Q3 25 | 4.6% | -112.8% | ||
| Q2 25 | 4.3% | -69.0% | ||
| Q1 25 | 7.3% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | 8.8% | -95.7% | ||
| Q2 24 | 7.1% | -89.5% | ||
| Q1 24 | 8.6% | -156.8% |
| Q4 25 | — | $-1.28 | ||
| Q3 25 | — | $-1.81 | ||
| Q2 25 | — | $-1.17 | ||
| Q1 25 | — | $-1.57 | ||
| Q4 24 | — | $-1.34 | ||
| Q3 24 | — | $-1.40 | ||
| Q2 24 | — | $-1.52 | ||
| Q1 24 | — | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.8M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $395.1M | $-80.0M |
| 总资产 | $500.7M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $3.8M | $421.0M | ||
| Q3 25 | $4.6M | $202.5M | ||
| Q2 25 | $4.8M | $176.3M | ||
| Q1 25 | $5.5M | $127.1M | ||
| Q4 24 | $22.7M | $174.0M | ||
| Q3 24 | $33.2M | $150.6M | ||
| Q2 24 | $53.4M | $480.7M | ||
| Q1 24 | $87.9M | $112.3M |
| Q4 25 | $395.1M | $-80.0M | ||
| Q3 25 | $379.8M | $9.2M | ||
| Q2 25 | $374.1M | $151.3M | ||
| Q1 25 | $368.6M | $144.2M | ||
| Q4 24 | $367.6M | $255.0M | ||
| Q3 24 | $346.6M | $346.8M | ||
| Q2 24 | $338.1M | $432.4M | ||
| Q1 24 | $331.6M | $140.3M |
| Q4 25 | $500.7M | $1.5B | ||
| Q3 25 | $503.8M | $1.2B | ||
| Q2 25 | $471.9M | $1.3B | ||
| Q1 25 | $455.3M | $1.3B | ||
| Q4 24 | $453.4M | $1.5B | ||
| Q3 24 | $428.9M | $1.5B | ||
| Q2 24 | $418.1M | $1.6B | ||
| Q1 24 | $417.5M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.9M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $12.4M | $-100.8M |
| 自由现金流率自由现金流/营收 | 7.6% | -48.6% |
| 资本支出强度资本支出/营收 | 0.9% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-36.2M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $13.9M | $-99.8M | ||
| Q3 25 | $-24.6M | $-91.4M | ||
| Q2 25 | $-10.9M | $-108.3M | ||
| Q1 25 | $12.5M | $-166.5M | ||
| Q4 24 | $-7.6M | $-79.3M | ||
| Q3 24 | $-17.5M | $-67.0M | ||
| Q2 24 | $-33.9M | $-77.0M | ||
| Q1 24 | $5.6M | $-190.7M |
| Q4 25 | $12.4M | $-100.8M | ||
| Q3 25 | $-24.7M | $-92.7M | ||
| Q2 25 | $-13.4M | $-110.7M | ||
| Q1 25 | $-10.5M | $-167.8M | ||
| Q4 24 | $-11.3M | $-79.5M | ||
| Q3 24 | $-20.3M | $-68.6M | ||
| Q2 24 | $-34.5M | $-79.0M | ||
| Q1 24 | $5.2M | $-193.9M |
| Q4 25 | 7.6% | -48.6% | ||
| Q3 25 | -21.4% | -58.0% | ||
| Q2 25 | -11.1% | -66.5% | ||
| Q1 25 | -10.2% | -120.5% | ||
| Q4 24 | -8.4% | -48.3% | ||
| Q3 24 | -22.1% | -49.2% | ||
| Q2 24 | -40.6% | -53.7% | ||
| Q1 24 | 6.7% | -178.2% |
| Q4 25 | 0.9% | 0.5% | ||
| Q3 25 | 0.1% | 0.8% | ||
| Q2 25 | 2.0% | 1.5% | ||
| Q1 25 | 22.2% | 1.0% | ||
| Q4 24 | 2.7% | 0.1% | ||
| Q3 24 | 3.1% | 1.2% | ||
| Q2 24 | 0.8% | 1.4% | ||
| Q1 24 | 0.5% | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | -4.63× | — | ||
| Q2 25 | -2.12× | — | ||
| Q1 25 | 1.64× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -2.16× | — | ||
| Q2 24 | -5.58× | — | ||
| Q1 24 | 0.85× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NPK
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
